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SUMMARY
The aims were to (1) investigate the aetiology of probable meningococcal disease, where a clinical
diagnosis is made in the absence of laboratory data, and (2) evaluate the impact of the Men C
vaccination programme in England and Wales. Multiple linear regression analyses were carried
out using data reported to Enhanced Surveillance of Meningococcal Disease (ESMD) and
laboratory reports of isolates of organisms causing symptoms that mimic meningococcal disease.
Conﬁrmed meningococcal disease appeared to be a signiﬁcant predictor of probable disease.
Thus, an additional reduction in meningococcal disease attributable to the serogroup C
vaccination campaign was evident in probable disease over and above that observed in conﬁrmed
cases alone. Enteroviruses were a signiﬁcant contributor to cases of probable meningitis and
inﬂuenza appeared to be a signiﬁcant contributor to probable cases of septicaemia. This analysis
conﬁrms the success seen following the Men C vaccination campaign and gives an indication of
the aetiologies of other causes of probable meningitis and septicaemia reported to ESMD.
INTRODUCTION
Meningococcal disease, including meningitis and
septicaemia, is caused by the organism Neisseria
meningitidis. The majority of meningococcal infec-
tions occur in infants <5 years of age, with a peak
incidence in those <1 year [1]. There is a secondary
peak in incidence in young adults aged between 15
and 19 years of age. Most infections in the United
Kingdom are due to serogroups B and C. The case
fatality is y10%, with more deaths occurring from
septicaemia than meningitis [1].
A national vaccination campaign for serogroup C
meningococcal disease began in the United Kingdom
on29November 1999,when anewmeningococcal con-
jugate serogroup C vaccine (Men C) was introduced
into the routine childhood schedule alongside a catch-
up programme in older children [2]. A phased intro-
duction was necessary due to limited supplies of the
vaccine, initially targeting high-risk groups (infants,
and teenagers aged 15–17 years) [3].
The positive impact of the campaign was reﬂected
in a decline in isolates and samples of serogroup C,
but not serogroup B, meningococcal disease referred
to the Health Protection Agency Meningococcal
Reference Unit (MRU) in vaccinated age groups [4].
Although improved methods for laboratory con-
ﬁrmation, in particular PCR [5], are available, it is not
possible to conﬁrm all cases of meningococcal disease.
Enhanced Surveillance of Meningococcal Disease
(ESMD) was introduced to improve estimates of the
burden of meningococcal disease prior to implemen-
tation of the Men C vaccine and to monitor meningo-
coccal disease post-implementation. In the ESMD
programme, information on clinically diagnosed
meningococcal disease is reconciled with laboratory
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data from the MRU. When a case has not been con-
ﬁrmed by a laboratory, it is classiﬁed as a probable
case based on clinical case deﬁnitions. Unlike con-
ﬁrmed cases, probable disease has shown no obvious
trend among the age groups vaccinated with Men C,
suggesting that some probable cases may be caused by
other pathogens. Many diﬀerent organisms can cause
symptoms that may be mistaken for meningococcal
disease, particularly septicaemia.
In order to calculate the impact of vaccination on
probable meningococcal disease, the aetiology of these
probable cases must ﬁrst be determined. ESMD was
used to examine the relationship between probable and
conﬁrmed cases and to estimate the possible contri-
bution of viral and other causes of meningitis and
septicaemia. As meningococcal disease shows a clear
seasonality, any seasonal pattern in probable disease
should correspond to that in conﬁrmed disease.
Seasonal patterns in cases reported to ESMD between
January 1999 and June 2003 were, therefore, investi-
gated using statistical models and laboratory data.
The objectives were to (1) determine the aetiology of
probable meningococcal disease, (2) evaluate the
impact of the Men C vaccine on these probable cases,
and (3) compare the aetiology of probable cases with
a diagnosis of meningitis to those with a diagnosis of
septicaemia.
METHODS
Data sources
ESMD
All cases of meningococcal disease from England and
Wales reported through ESMD between 1 January
1999 and 30 June 2003 were included in this analysis.
Probable casesofmeningococcaldiseasearedeﬁnedas:
meningitis, septicaemia or other invasive disease in the
absence of laboratory conﬁrmation where N. meningitidis is
thought to be the most likely diagnosis by the clinician
managing the case and/or the Consultant in Communicable
Disease Control [6].
Cases of laboratory-conﬁrmed meningococcal disease
were classiﬁed into serogroup B, serogroup C or
‘other’ (ungrouped or attributed to serogroupsW135,
Y, 29-E, X or Z). Additionally, cases of conﬁrmed
and probable meningococcal disease were grouped by
diagnosis (meningitis vs. septicaemia) for further
analysis. Cases were grouped into the following age
categories ; <1, 1–4, 5–14, 15–19 and o20 years.
Four-week totals were calculated.
Laboratory reports
Many diﬀerent organisms can cause symptoms that
may be mistaken for meningococcal disease, particu-
larly septicaemia. The possible organisms for inclusion
in the model were identiﬁed by enhanced surveillance
in 1998, where alternative diagnoses were recorded for
cases initially suspected to be attributable to meningo-
coccal disease [3]. These include pneumococcal infec-
tion, streptococcal (A or B) infection, Haemophilus
inﬂuenzae, enterovirus (type 70, 71 or untyped),
coxsackie B virus, echovirus, inﬂuenza (A, B or un-
grouped), RSV, herpes simplex virus, varicella zoster
virus, parvovirus, and mumps virus. In order to
qualify for consideration in the regression models,
laboratory reports for these pathogens had to exhibit
a seasonal pattern and be reported frequently enough
that their seasonality was apparent.
Four-week totals of laboratory reports of isolates
of the organisms identiﬁed above for the period 1
January 1999 to 30 June 2003 were obtained from
conﬁrmed infections reported to the Health Pro-
tection Agency Centre for Infections from a network
of over 250 laboratories in England and Wales.
Evaluating impact of Men C vaccine programme
Multiple linear regression analyses, carried out in
Microsoft Excel, were used to assess the contribution
of meningococci and other organisms to probable
cases of meningococcal disease (including septicaemia,
meningitis and other invasive diseases combined)
and subsequently to estimate the number of cases of
probable meningococcal disease attributable to sero-
group C N. meningitidis. This method relies on the
seasonal variation of meningococcal disease and other
infections included in the model, and how the vari-
ation is reﬂected in the number of four-weekly total
reports. The methods have been used in a similar way
to investigate hospital admissions due to rotavirus [7],
and the contribution of RSV to bronchiolitis and
pneumonia-associated hospitalizations [8]. The model
associates ESMD four-weekly totals of conﬁrmed
meningococcal disease, as well as other organisms
that can cause symptoms that may be mistaken for
meningococcal disease, with probable cases. The
goodness-of-ﬁt of the model is denoted by R2.
The formula for estimated probable cases Yj in the
4-week period j :
Yj=C+
X
aiLij:
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Where Lij is the number of laboratory or ESMD
reports of type i in the 4-week period j and ai is the
number of probable cases of meningococcal disease
associated with each report of type i. C is a constant
representing the background number of probable
cases in each 4-week period associated with other
infectious or non-infectious causes of meningitis,
septicaemia or other clinical illness which may be
mistaken for either of these syndromes, where the
temporal trend is not strong enough to be individually
signiﬁcant. The values of a were estimated by least
squares regression. An organism was only retained in
the model if a was found to be signiﬁcantly associated
with probable disease (P<0.05). This method
assumes that a conﬁrmed case of each organism is
associated with a constant number of probable cases
of meningococcal disease.
The statistical models for each age group generated
a value for the number of probable cases associated
with a single conﬁrmed case of serogroup C (a). These
values were applied to six-monthly totals of conﬁrmed
serogroup C cases to estimate the total number of
cases of probable meningococcal disease reported in
ESMD that were due to serogroup C meningococcal
infection. Similarly, six-monthly rates for probable
serogroup C disease were estimated per 100 000 of
population based on age-speciﬁc 2001 population
estimates for England and Wales.
Further investigating the aetiology of probable cases
by diagnosis
To further investigate the aetiology of probable
meningococcal disease by diagnoses, ESMD data
were broken down into probable septicaemia and
conﬁrmed serogroup-speciﬁc septicaemia cases and
probable meningitis and conﬁrmed serogroup-speciﬁc
meningitis cases. Multiple linear regression analyses
were carried out, as described above, for the
diagnoses of meningitis and septicaemia separately.
Laboratory data for the identical organisms men-
tioned previously were included in the models.
RESULTS
Enhanced surveillance of meningococcal disease
Between 1 January 1999 and 30 June 2003, 17 440
cases of meningococcal disease were identiﬁed by
ESMD. Of these, 7471 (43%) were probable cases
rather than laboratory conﬁrmed. Of the 9969 con-
ﬁrmed cases, 67% were serogroup B, 22% were
serogroup C and 11% were ungrouped or another
serogroup (classiﬁed as ‘other’ ; Table 1). There were
more cases of septicaemia than meningitis overall,
serogroup C was more common in cases of septi-
caemia and in older age groups, and amongst prob-
able cases a lower proportion had a diagnosis of
septicaemia (Table 1).
The seasonal pattern of probable meningococcal
disease is less striking than conﬁrmed meningococcal
disease, and seasonality varied among age groups and
by disease presentation (Fig. 1). Although there is a
peak in both meningitis and septicaemia in the winter,
the peaks are more marked for septicaemia (Fig. 2).
Laboratory reports
Some infections display regular annual winter peaks
(e.g. N. meningitidis, S. pneumoniae, RSV) and others
are less regular and have peaks in the summer (e.g.
enteroviruses; Fig. 3). Enteroviruses, a major cause of
viral meningitis, have a summer peak in reports seen
each year, and a particularly large outbreak occurred
in 2000 [9].
Table 1. Breakdown of cases reported to Enhanced Surveillance of Meningococcal Disease (ESMD) by age group,
serogroup and diagnosis, January 1999 to end June 2003*
Age
group
(yr)
Meningitis (5550, 32%) Septicaemia (8583, 49%)
B (%) C (%) Other (%) Probable (%) B (%) C (%) Other (%) Probable (%)
<1 488 (40) 35 (3) 82 (7) 599 (50) 731 (36) 93 (5) 90 (4) 1100 (55)
1–4 423 (42) 65 (7) 82 (8) 436 (43) 1276 (44) 300 (10) 165 (6) 1157 (40)
5–14 233 (27) 42 (5) 60 (7) 531 (61) 524 (34) 237 (15) 95 (6) 684 (45)
15–19 316 (43) 72 (10) 40 (6) 304 (41) 219 (37) 157 (26) 20 (3) 201 (34)
o20 518 (30) 249 (15) 93 (5) 863 (50) 527 (35) 470 (32) 140 (9) 351 (24)
* Cases reported to ESMD with a diagnosis of both meningitis and septicaemia, other invasive disease excluding meningitis
and septicaemia or where the diagnosis was not known have been excluded from this table, as have cases for which the age
group was not known.
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Evaluating the impact of the Men C vaccine
programme
In assessing the contribution of meningococci and
other organisms to probable cases of meningococcal
disease, the model appeared to ﬁt best in children aged
1–4 years (R2=0.77) and worst in teenagers aged
15–19 years (R2=0.48, Table 2). Serogroup C
meningococcal disease was a signiﬁcant contributor in
all age groups except for the o20 years group. In
these age groups y20% of probable cases were
attributed to serogroup C meningococcal disease.
Inﬂuenza was found to be signiﬁcantly associated
with probable meningococcal disease in the 1–4, 5–14
and 15–19 years age groups, and enterovirus was
signiﬁcantly associated with probable meningococcal
disease in infants, children aged 5–14 years, ando20-
year-olds. Serogroup B and other serogroups were
also important contributors in the o20 years age
group. The values of a, the number of probable cases
of serogroup C meningococcal disease associated with
a conﬁrmed case, showed that the estimated increase
in burden of meningococcal serogroup C is greatest in
the younger age groups, with a 228% increase in cases
in the <1 year age group (Table 2). This falls with
increasing age to 46% in the 15–19 years age group.
The additional number of probable cases that were
estimated to be due to serogroup C meningococcal
disease was calculated for each age group by a
6-month period between week 1 (1999) and week 26
(2003). Overall, an additional 1170 cases of probable
disease were estimated to be attributable to serogroup
C meningococcal infection (Table 3). An estimated
1009 cases of serogroupCmeningococcal disease (both
conﬁrmed and probable) occurred in the ﬁrst 6months
of 1999 compared to only 79 in the same period of
2003. This represents a reduction of y92%, higher
than that estimated from surveillance of conﬁrmed
0
20
40
60
80
100
120
140
160
Date
N
um
be
r o
f c
as
es
 re
po
rte
d 
to
 E
SM
D
Unconfirmed
B
C
Other
Jan.
1999
Apr. July Oct. Jan.
2000
Apr. July Oct. Jan.
2001
Apr. July Oct. Jan.
2002
Apr. July Oct. Jan.
2003
Apr. July
Fig. 1. Cases of conﬁrmed and probable meningococcal disease as reported to ESMD by week (week 1, 1999 to week 27,
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Fig. 2. Seasonal patterns of meningitis and septicaemia
(conﬁrmed and probable) reported to ESMD, January 1999
to June 2003.
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cases alone (just below 90%). The greatest reduction in
the rate of serogroup C meningococcal disease (con-
ﬁrmed and probable) before and after the vaccination
campaign is seen in infants<1 year old (Table 4).
Further investigating the aetiology of probable cases
by diagnosis
Meningitis
For meningitis, the highest R2 value was seen in the
<1 year age group (R2=0.57). This was followed by
the o20 and 5–14 years groups, with an R2 of 0.53
and 0.40 respectively (Fig. 4). The model ﬁts particu-
larly poorly in the 15–19 and 1–4 years age groups.
The contribution of meningococcal infection to
probable meningitis varied by age. In the <1, 5–14
ando20 years age groups, between 26% and 38% of
all probable cases were attributed to meningococcal
disease caused by serogroup B and other serogroups.
In the 1–4, 5–14 and 15–19 years age groups, between
10% and 21% of all probable cases were attributed to
meningococcal serogroup C. Enterovirus infection
was signiﬁcantly associated with probable disease
in all age groups apart from 1–4 and 15–19 years.
Total confirmed meningococcal disease
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No other organism was found to be signiﬁcantly
associated with probable disease. In children<1 year
old, 62% of probable cases were attributed to
enterovirus infection. In all ages apart from those<1
year old, a constant was retained and accounted for
between 34% and 90% of probable cases.
Septicaemia
For septicaemia, the highest R2 value was seen in the
1–4 years age group (R2=0.75). This was followed by
theo20, 5–14, 15–19 and<1 years age groups, with
R2 values ranging between 0.44 and 0.53 (Fig. 5). The
contribution of meningococcal infection to probable
cases of septicaemia varied. Between 18% and 34%
of all probable cases of septicaemia were attributed to
meningococcal serogroup C disease in all age groups
apart from the o20 years age group. In the latter,
meningococcal disease caused by serogroup B and
other serogroups explained 70% of probable cases.
Enteroviruses were again signiﬁcantly associated with
probable meningococcal disease in those aged <1
year. Inﬂuenza also appeared to be associated with
probable septicaemia in the 1–4 and 5–14 years
Table 2. Results of multiple linear regression by age group: ﬁt of the model (R2), signiﬁcant contributors to
probable meningococcal disease, and number of probable cases associated with a single conﬁrmed case of serogroup
C (a)
Age group (yr) a 95% CI R2 Signiﬁcant organisms*
<1 2.28 1.58–2.98 0.56 Constant, serogroup C, enteroviruses
1–4 0.88 0.67–1.09 0.77 Constant, serogroup C, inﬂuenza
5–14 0.75 0.49–1.01 0.61 Constant, serogroup C, enteroviruses, inﬂuenza
15–19 0.46 0.27–0.66 0.48 Constant, serogroup C, inﬂuenza
o20 n.a. n.a. 0.61 Constant, serogroup B and other, enteroviruses
n.a., Not available as serogroup C not signiﬁcant contributor of probable disease in this group.
* All organisms identiﬁed as causing symptoms that mimic meningococcal disease were ﬁtted to the model but only retained
if found to be signiﬁcant (P<0.05).
Table 3. Total number conﬁrmed and estimated number probable cases attributed to serogroup C meningococcal
infection by age group (week 1, 1999 to week 26, 2003)
Age
group
(yr) Cases
Weeks
Total 95% CI
1999 2000 2001 2002 2003
1–26 27–52 1–26 27–52 1–26 27–52 1–26 27–52 1–26
<1 Conﬁrmed* 59 49 19 8 10 5 0 3 2 155
Probable# 135 112 43 18 23 11 0 7 5 353 245–462
1–4 Conﬁrmed 142 92 145 26 21 11 11 1 11 460
Probable 125 81 128 23 18 10 10 1 10 405 308–501
5–14 Conﬁrmed 121 74 115 28 9 4 6 1 4 362
Probable 91 56 86 21 7 3 5 1 3 272 177–366
15–19 Conﬁrmed 119 79 47 17 20 7 10 5 2 306
Probable 55 36 22 8 9 3 5 2 1 141 83–202
o20 Conﬁrmed 163 98 179 108 134 62 74 39 42 899
Probable 0 0 0 0 0 0 0 0 0 0
All ages Conﬁrmed 604 392 505 187 194 89 101 49 61 2182
Probable 405 285 279 70 57 27 19 11 18 1170
Total 1009 677 784 257 251 116 120 60 79 3352
* Observed number of conﬁrmed cases.
# Estimated number of probable cases.
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age groups. In all ages a constant was retained,
and accounted for between 30 and 66% of probable
cases.
DISCUSSION
Conﬁrmed meningococcal disease was signiﬁcantly
associated with probable meningitis and septicaemia
for all age groups conﬁrming that N. meningitidis
contributes to probable cases reported in the ESMD.
This justiﬁes the inclusion of probable cases in the
enhanced surveillance conducted in England and
Wales.
Over and above the observed reduction in con-
ﬁrmed cases, an additional reduction in meningo-
coccal disease attributable to the serogroup C
vaccination campaign can be seen in probable cases.
This reduction is most striking in infants, in whom
routine coverage for Men C was almost 90% by the
end of June 2003 [10]. These children, along with
teenagers aged 15–17 years, were the ﬁrst to receive
the vaccine at the start of the campaign, and the re-
duction in conﬁrmed and probable disease is consist-
ent with high levels of coverage achieved early in the
vaccination campaign [4]. As for conﬁrmed disease,
serogroup C appeared to be a more important
contributor to probable septicaemia than probable
meningitis. This explains the observation of a
substantial rise in notiﬁed meningococcal septicaemia
between 1989 and 1995, accompanying the increased
proportion of serogroup C amongst conﬁrmed
cases [11]. As septicaemia is associated with a higher
case-fatality ratio than meningitis [1], this suggests
that the impact of the vaccination campaign on
deaths from meningococcal infection is likely to be
dramatic.
The aetiology of probable meningococcal disease
and the suitability of the model in attributing causes
to these cases vary between the diﬀerent age groups
and by diagnosis. The goodness of ﬁt of the model
depends upon the organisms included. The model is
limited to those organisms for which surveillance data
are available and excludes as yet unrecognized or-
ganisms, organisms for which there are no diagnostic
tests or those not routinely reported, for example
Epstein–Barr virus. In addition, organisms that do
not have a clear seasonality will not be detected by
this modelling.
In addition to conﬁrmed N. meningitidis, en-
teroviruses and inﬂuenza were signiﬁcant con-
tributors to probable cases reported in the ESMD.
Enterovirus appeared to be a more important con-
tributor to probable meningitis, while inﬂuenza was
more important for septicaemia.
Even though the ﬁt (R2 range 0.40–0.57) was not
great, the models strongly suggest that enterovirus
Table 4. Rate of serogroup C meningococcal disease (conﬁrmed and probable) by age group (weeks 1–26, 1999 and
weeks 1–26, 2003)
Age
group
(yr) Cases of serogroup C
Rate*
Weeks 1–26 (1999) Weeks 1–26 (2003) Rate diﬀerence
<1 Conﬁrmed 10.02 0.34 9.68
Estimated number of probable 22.85 0.77 22.07
Total 32.87 1.11 31.75
1–4 Conﬁrmed 5.69 0.44 5.25
Estimated number of probable 5.00 0.39 4.62
Total 10.69 0.83 9.86
5–14 Conﬁrmed 1.80 0.06 1.74
Estimated number of probable 1.35 0.04 1.30
Total 3.15 0.10 3.04
15–19 Conﬁrmed 3.69 0.06 3.63
Estimated number of probable 1.70 0.03 1.67
Total 5.39 0.09 5.30
o20 Conﬁrmed 0.42 0.11 0.31
Estimated number of probable 0.00 0.00 0.00
Total 0.42 0.11 0.31
* Six-monthly rate is estimated per 100 000 population based on age-speciﬁc 2001 population estimates for England and
Wales.
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was a major contributor to the peak in cases of
probable meningitis seen in 2000 for numerous age
groups. This was particularly true for the <1 year
group, where enterovirus contributed to over 60% of
probable cases. The peak in viral meningitis notiﬁ-
cations in the summer of 2000 was attributed to an
increase in echovirus type 13 [9]. Suspected men-
ingococcal meningitis, therefore, should always be
investigated for enterovirus. Isolation of enterovirus
from the CSF is not always possible, but viral
stool culture and enterovirus RNA detection can be
used [12, 13]. Improving the laboratory diagnosis of
such cases could lead to cost savings for NHS
care [14].
Inﬂuenza appeared to be a signiﬁcant contributor
to probable cases of septicaemia in numerous age
groups. The symptoms of inﬂuenza are non-speciﬁc
and can mimic the symptoms of septicaemia especially
5–14 years, R2=0·40 
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Fig. 4. Multiple regression models, ﬁtted to probable cases of meningococcal meningitis, for age groups where model had
‘good ﬁt’ (R2>0.40).
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in young infants. Inﬂuenza can also predispose to
meningococcal disease and may be responsible for a
small excess number of cases [15]. Inﬂuenza is also
under-recognized in other paediatric infections [8]
and, therefore, clinicians should be more aware and
consider investigation for inﬂuenza more often.
In addition to demonstrating that ESMD provides
additional value over routine surveillance of conﬁrmed
infections, this study has identiﬁed areas for im-
provement. Ideally, cases of probable and conﬁrmed
disease reported to ESMD should contain infor-
mation on positive and negative results for laboratory
investigations for meningococcal and other infections.
This would result in more reliable data on the total
incidence of meningococcal disease, including cases
that would otherwise be missed.
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Fig. 5. Multiple regression models ﬁtted to probable cases of meningococcal septicaemia, by age group.
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